Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
NCT ID: NCT01447225
Last Updated: 2016-09-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
43 participants
INTERVENTIONAL
2011-10-31
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
NCT00734305
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
NCT01001221
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
NCT01297452
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
NCT03811652
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
NCT02915172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MM-121 plus Gemcitabine
escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
MM-121
MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
Gemcitabine
administered IV at 1000 mg/m2 or 1250 mg/m2
MM-121 plus Carboplatin
carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
MM-121
MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
Carboplatin
administered at AUC 6
MM-121 plus Pemetrexed
pemetrexed at 500 mg/m2 with escalating doses of MM-121 on Day 1 of every 3 week cycle
MM-121
MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
Pemetrexed
administered IV at 500 mg/m2
MM-121 plus Cabazitaxel
escalating doses of MM-121 and cabazitaxel on Day 1 of every 3 week cycle
MM-121
MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
Cabazitaxel
administered IV at 20 mg/m2 or 25 mg/m2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MM-121
MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
Carboplatin
administered at AUC 6
Pemetrexed
administered IV at 500 mg/m2
Cabazitaxel
administered IV at 20 mg/m2 or 25 mg/m2
Gemcitabine
administered IV at 1000 mg/m2 or 1250 mg/m2
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years of age
* Adequate liver and kidney function
Exclusion Criteria
* No known HIV, Hepatitis C or B
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Merrimack Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Victor Moyo, MD
Role: STUDY_DIRECTOR
Merrimack Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lafayette, Indiana, United States
Buffalo, New York, United States
Cincinnati, Ohio, United States
Philadelphia, Pennsylvania, United States
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MM-121-06-01-06 (TCD11694)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.